NABIHAHTAYOBNABIHAH TAYOB12385TAYOB, NABIHAHAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonBiostatisticsGI Medical OncologyLeukemiaSurgical OncologyMD AndersonHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorJEAN NICOLASVAUTHEYJEAN NICOLAS VAUTHEY8766VAUTHEY, JEAN NICOLASProfessorELIZABETH ANNMITTENDORFELIZABETH ANN MITTENDORF9277MITTENDORF, ELIZABETH ANNAssociate ProfessorAHMEDKASEBAHMED KASEB9430KASEB, AHMEDAssociate ProfessorZIDINGFENGZIDING FENG9893FENG, ZIDINGProfessor23043074Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, Fry CD, White ES, Sisson TH, Tayob N, Carnemolla B, Orecchia P, Flaherty KR, Hershenson MB, Murray S, Martinez FJ, Moore BB, COMET InvestigatorsAmerican journal of physiology. Lung cellular and molecular physiologyPeriostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15; 303(12):L1046-56.Am J Physiol Lung Cell Mol Physiol2012-10-05T00:00:002012Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis.74Professor10Assistant Professor21Chair14Associate ProfessorBreast Surgical Oncology1400 Pressler StHouston77030-4008TX2.717170.00477369297research areas3.034490.043176640coauthor of151.1517.047460similar to1192selected publicationsAuthorship 37379510Authorship 847180Authorship 854381Authorship 865927Statistics and Probability LettersNonparametric restricted mean analysis across multiple follow-up intervals. Statistics and Probability Letters. 109:152-158.Nonparametric restricted mean analysis across multiple follow-up intervalsChestIdiopathic pulmonary fibrosis. Chest. 149:491-498.Idiopathic pulmonary fibrosisClinical Gastroenterology and HepatologyImproved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clinical Gastroenterology and Hepatology. 14:469-475.e2.Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm29301497Tayob N, Richardson P, White DL, Yu X, Davila JA, Kanwal F, Feng Z, El-Serag HBBMC medical research methodologyEvaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1.BMC Med Res Methodol2018-01-04T00:00:002018Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.true1ProfessorProfessortrue1Assistant ProfessorAssistant ProfessorAuthorship 8899401D008103Disorders2639370.591647Liver CirrhosisD000509Chemicals & Drugs1022380.885366alpha-FetoproteinsD006528Disorders47920290.403307Carcinoma, HepatocellularD001943Disorders1432156510.17611Breast NeoplasmsAuthorship 8998233Authorship 9000964Authorship 9003663Authorship 9005563Authorship 9025094Authorship 9026012Authorship 9026452Authorship 9029801Authorship 9041085Authorship 9044841Authorship 9046151Authorship 9087461Authorship 9135595Authorship 9212581Authorship 9220401Authorship 9253352Authorship 9333543Authorship 9363482Authorship 938187119622357Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, Wang F, Bandipalliam P, Syngal S, Gruber SBGastroenterologyCalculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009 Nov; 137(5):1621-7.Gastroenterology2009-07-18T00:00:002009Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.19861671Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal SJAMARisk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009 Oct 28; 302(16):1790-5.JAMA2009-10-28T00:00:002009Risk of pancreatic cancer in families with Lynch syndrome.21148225Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KRThe European respiratory journalPulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J. 2011 Jul; 38(1):176-83.Eur Respir J2010-12-09T00:00:002010Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema.21655324Moodley P, Shah NS, Tayob N, Connolly C, Zetola N, Gandhi N, Friedland G, Sturm AWPloS oneSpread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa. PLoS One. 2011; 6(5):e17513.PLoS One2011-05-31T00:00:002011Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa.24231810Schmidt SL, Tayob N, Han MK, Zappala C, Kervitsky D, Murray S, Wells AU, Brown KK, Martinez FJ, Flaherty KRChestPredicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest. 2014 Mar 01; 145(3):579-585.Chest2014-03-01T00:00:002014Predicting pulmonary fibrosis disease course from past trends in pulmonary function.24767767Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, Moore BB, White ES, Flaherty KR, Huffnagle GB, Martinez FJ, COMET InvestigatorsThe Lancet. Respiratory medicineLung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014 Jul; 2(7):548-56.Lancet Respir Med2014-04-21T00:00:002014Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.24719282Tayob N, Murray SBiostatistics (Oxford, England)Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events. Biostatistics. 2015 Jan; 16(1):73-83.Biostatistics2014-04-08T00:00:002014Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events.24779680Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, Criner GJ, Casaburi R, Connett J, Lazarus SC, Albert R, Woodruff P, Martinez FJAmerican journal of respiratory and critical care medicinePredictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014 Jun 15; 189(12):1503-8.Am J Respir Crit Care Med2014-06-15T00:00:002014Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy.26425858Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, Wells AU, Schmidt SL, Martinez FJ, Flaherty KRChestIdiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest. 2016 Feb; 149(2):491-498.Chest2016-01-12T00:00:002016Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.26260109Tayob N, Lok AS, Do KA, Feng ZClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationImproved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):469-475.e2.Clin Gastroenterol Hepatol2015-08-07T00:00:002015Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm.26845527Tayob N, Do KA, Feng ZBiometricsUnbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design. Biometrics. 2016 09; 72(3):888-96.Biometrics2016-02-04T00:00:002016Unbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design.26858468Tayob N, Murray SStatistics & probability lettersNonparametric restricted mean analysis across multiple follow-up intervals. Stat Probab Lett. 2016 Feb 01; 109:152-158.Stat Probab Lett2016-02-01T00:00:002016Nonparametric restricted mean analysis across multiple follow-up intervals.28324918Tayob N, Murray SStatistics in medicineStatistical consequences of a successful lung allocation system - recovering information and reducing bias in models for urgency. Stat Med. 2017 07 10; 36(15):2435-2451.Stat Med2017-03-21T00:00:002017Statistical consequences of a successful lung allocation system - recovering information and reducing bias in models for urgency.28947036Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, Schmidt SL, Lagstein A, Myers JL, Gross BH, Kazerooni EA, Sundaram B, Chughtai AR, Martinez FJ, Flaherty KRRespiratory medicinePossible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med. 2017 10; 131:229-235.Respir Med2017-09-12T00:00:002017Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients.28482112Tayob N, Stingo F, Do KA, Lok ASF, Feng ZBiometricsA Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. Biometrics. 2018 03; 74(1):249-259.Biometrics2017-05-08T00:00:002017A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers.29485901Han MK, Tayob N, Murray S, Woodruff PG, Curtis JL, Kim V, Criner G, Galban CJ, Ross BD, Hoffman EA, Lynch DA, Kazerooni E, Martinez FJ, COPDGene and SPIROMICS InvestigatorsAmerican journal of respiratory and critical care medicineAssociation between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials. Am J Respir Crit Care Med. 2018 07 15; 198(2):265-267.Am J Respir Crit Care Med2018-07-15T00:00:002018Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials.30557738Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HBClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationValidation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1886-1893.e5.Clin Gastroenterol Hepatol2018-12-14T00:00:002018Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis.30635188Nelson DB, Tayob N, Mitchell KG, Correa AM, Hofstetter WL, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Antonoff MB, Roth JA, Rice DC, Vauthey JN, Mehran RJThe Journal of thoracic and cardiovascular surgerySurgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. J Thorac Cardiovasc Surg. 2019 04; 157(4):1648-1655.J Thorac Cardiovasc Surg2018-11-26T00:00:002018Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases.30456786Xia M, Murray S, Tayob NBiometricsNonparametric group sequential methods for evaluating survival benefit from multiple short-term follow-up windows. Biometrics. 2019 06; 75(2):494-505.Biometrics2019-04-04T00:00:002019Nonparametric group sequential methods for evaluating survival benefit from multiple short-term follow-up windows.D008113Disorders90245500.295538Liver NeoplasmsDepartment of MedicineMedicine-Gastroenterology & HepatolMedicine-VAMC Health Services ResBaylor College of MedicinePETERRICHARDSONPETER RICHARDSON29.70041420000000-95.38988870000000230RICHARDSON, PETERAssistant ProfessorFASIHAKANWALFASIHA KANWAL29.70503200000000-95.407546000000004180KANWAL, FASIHAProfessorHASHEMEL-SERAGHASHEM EL-SERAG29.70560750000000-95.3846773000000068EL-SERAG, HASHEMProfessorAuthorship 953531231395367Nelson DB, Tayob N, Nguyen QN, Erasmus J, Mitchell KG, Hofstetter WL, Sepesi B, Antonoff MB, Mehran RJThe Journal of thoracic and cardiovascular surgeryLocal failure after stereotactic body radiation therapy or wedge resection for colorectal pulmonary metastases. J Thorac Cardiovasc Surg. 2019 10; 158(4):1234-1241.e16.J Thorac Cardiovasc Surg2019-05-11T00:00:002019Local failure after stereotactic body radiation therapy or wedge resection for colorectal pulmonary metastases.Authorship 958082331663647Xia M, Murray S, Tayob NStatistics in medicineRegression analysis of recurrent-event-free time from multiple follow-up windows. Stat Med. 2020 01 15; 39(1):1-15.Stat Med2019-10-30T00:00:002019Regression analysis of recurrent-event-free time from multiple follow-up windows.true1ProfessorProfessorAuthorship 961140331732980Xia M, Murray S, Tayob NStatistics in medicineNonparametric group sequential methods for recurrent and terminal events from multiple follow-up windows. Stat Med. 2019 12 30; 38(30):5657-5669.Stat Med2019-11-15T00:00:002019Nonparametric group sequential methods for recurrent and terminal events from multiple follow-up windows.Authorship 996626132768590Tayob N, Corley DA, Christie I, Almers L, Rahal AK, Richardson P, White DL, Davila J, Kanwal F, El-Serag HBClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationValidation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2021 07; 19(7):1443-1450.e6.Clin Gastroenterol Hepatol2020-08-05T00:00:002020Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies.Authorship 9999071032959883Tolaney SM, Lydon CA, Li T, Dai J, Standring A, Legor KA, Caparrotta CM, Schenker MP, Glazer DI, Tayob N, DuBois SG, Meyerhardt JA, Taplin ME, Johnson BEJournal of the National Cancer InstituteThe Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2021 11 02; 113(11):1453-1459.J Natl Cancer Inst2021-11-02T00:00:002021The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute.Authorship 1006145533257427Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SMClinical cancer research : an official journal of the American Association for Cancer ResearchClinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):983-991.Clin Cancer Res2020-11-30T00:00:002020Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.Authorship 1006905533320362Seah DS, Leone JP, Openshaw TH, Scott SM, Tayob N, Hu J, Lederman RI, Frank ES, Sohl JJ, Stadler ZK, Erick TK, Silverman SG, Peppercorn JM, Winer EP, Come SE, Lin NUCancerPerceptions of patients with early stage breast cancer toward research biopsies. Cancer. 2021 04 15; 127(8):1208-1219.Cancer2020-12-15T00:00:002020Perceptions of patients with early stage breast cancer toward research biopsies.Authorship 10116261Authorship 10124071333590387Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NUBreast cancer research and treatmentTwenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852.Breast Cancer Res Treat2021-02-16T00:00:002021Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.33637350Schrier E, Xiong N, Thompson E, Poort H, Schumer S, Liu JF, Krasner C, Campos SM, Horowitz NS, Feltmate C, Konstantinopoulos PA, Dinardo MM, Tayob N, Matulonis UA, Patel M, Wright AAGynecologic oncologyStepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.Gynecol Oncol2021-02-23T00:00:002021Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.Authorship 10135739Authorship 1013582633705205Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PAJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.J Clin Oncol2021-03-11T00:00:002021Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.33705745Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva AGastroenterologyInternational Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology. 2021 06; 160(7):2572-2584.Gastroenterology2021-03-09T00:00:002021International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.Authorship 10165322Authorship 1016942333893907Leone JP, Vallejo CT, Hassett MJ, Leone J, Graham N, Tayob N, Freedman RA, Tolaney SM, Leone BA, Winer EP, Lin NUBreast cancer research and treatmentFactors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212.Breast Cancer Res Treat2021-04-24T00:00:002021Factors associated with late risks of breast cancer-specific mortality in the SEER registry.33864933Singal AG, Tayob N, Mehta A, Marrero JA, Jin Q, Lau J, Parikh NDClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationDoylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2022 04; 20(4):953-955.e2.Clin Gastroenterol Hepatol2021-04-20T00:00:002021Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis.Authorship 1020165234077270Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop IJournal of clinical oncology : official journal of the American Society of Clinical OncologyAdjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.J Clin Oncol2021-06-02T00:00:002021Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.Authorship 1021087334120223Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SMBreast cancer research and treatmentChemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.Breast Cancer Res Treat2021-06-12T00:00:002021Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).Authorship 1024573334231078Leone JP, Vallejo CT, Hassett MJ, Leone J, Graham N, Tayob N, Freedman RA, Tolaney SM, Leone BA, Winer EP, Lin NUBreast cancer research and treatmentCorrection to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305.Breast Cancer Res Treat2021-08-01T00:00:002021Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry.Authorship 10255743Authorship 1025966434275766Occhiogrosso RH, Ren S, Tayob N, Li T, Gagnon HC, Paz A, Freedman RAClinical breast cancerFeasibility of an Online Patient Community to Support Older Women With Newly Diagnosed Breast Cancer. Clin Breast Cancer. 2022 02; 22(2):178-185.Clin Breast Cancer2021-06-12T00:00:002021Feasibility of an Online Patient Community to Support Older Women With Newly Diagnosed Breast Cancer.34302589Balch SM, Vaz-Luis I, Li T, Tayob N, Jain E, Helvie K, Buendia-Buendia JE, Shannon E, Isakoff SJ, Tung NM, Krop IE, Lin NU, Wagle N, Freedman RABreast cancer research and treatmentA phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Res Treat. 2021 Sep; 189(2):411-423.Breast Cancer Res Treat2021-07-24T00:00:002021A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.Authorship 1026747534349115Spring LM, Clark SL, Li T, Goel S, Tayob N, Viscosi E, Abraham E, Juric D, Isakoff SJ, Mayer E, Moy B, Supko JG, Tolaney SM, Bardia ANPJ breast cancerPhase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Aug 04; 7(1):103.NPJ Breast Cancer2021-08-04T00:00:002021Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.Authorship 1028373434433812Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SMNPJ breast cancerNivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110.NPJ Breast Cancer2021-08-25T00:00:002021Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.Authorship 10288891734472667Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NUThe oncologistProspective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933.Oncologist2021-09-24T00:00:002021Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.Authorship 10301577Authorship 10302051234548479Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SMNature communicationsMolecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563.Nat Commun2021-09-21T00:00:002021Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.34552099Konstantinopoulos PA, da Costa AABA, Gulhan D, Lee EK, Cheng SC, Hendrickson AEW, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Stover EH, Curtis J, Tayob N, Polak M, Chowdhury D, Matulonis UA, F?rkkil? A, D'Andrea AD, Shapiro GINature communicationsA Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574.Nat Commun2021-09-22T00:00:002021A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.34618932Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh NDHepatology (Baltimore, Md.)GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022 03; 75(3):541-549.Hepatology2021-12-17T00:00:002021GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.Authorship 10353642Authorship 10366882Authorship 1036773634990776Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, DeMeo M, Burstein HJ, Partridge AH, Winer EP, Krop IE, Tolaney SMInternational journal of radiation oncology, biology, physicsLocal Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):117-124.Int J Radiat Oncol Biol Phys2022-01-03T00:00:002022Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.34994617Parsons HA, Macrae ER, Guo H, Li T, Barry WT, Tayob N, Wulf GM, Isakoff SJ, Krop IEJCO precision oncologyPhase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precis Oncol. 2021 11; 5:896-903.JCO Precis Oncol2021-11-01T00:00:002021Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells.Authorship 10389127Authorship 10394551Authorship 10397713Authorship 10403872Authorship 10406402Authorship 10409951Authorship 10410991Authorship 1041813435213362Tayob N, Feng ZCancer biomarkers : section A of Disease markersPersonalized statistical learning algorithms to improve the early detection of cancer using longitudinal biomarkers. Cancer Biomark. 2022; 33(2):199-210.Cancer Biomark2022-01-01T00:00:002022Personalized statistical learning algorithms to improve the early detection of cancer using longitudinal biomarkers.35124267Tayob N, Kanwal F, Alsarraj A, Hernaez R, El-Serag HBClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationThe Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4.Clin Gastroenterol Hepatol2022-02-03T00:00:002022The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.35199349Tayob N, Lok ASF, Feng ZStatistics in medicineA multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. Stat Med. 2022 06 15; 41(13):2338-2353.Stat Med2022-02-23T00:00:002022A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers.35173164Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SMNPJ breast cancerCardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18.NPJ Breast Cancer2022-02-16T00:00:002022Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.35363308Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, Chittenden A, Kane S, Stokes S, Hughes ME, Kim JS, Umeton R, Awad MM, Konstantinopoulos PA, Yurgelun MB, Wolpin BM, Taplin ME, Newmark RE, Johnson BE, Lindeman NI, MacConaill LE, Garber JE, Lin NUClinical cancer research : an official journal of the American Association for Cancer ResearchIdentification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022 06 01; 28(11):2349-2360.Clin Cancer Res2022-06-01T00:00:002022Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.35339460Benhammou JN, Rich NE, Cholankeril G, Zhang P, Zeng W, Rao S, Tayob N, National Cancer Institute?s Translational Liver Consortium Early-Career Working GroupGastroenterologyDETECT: Development of Technologies for Early HCC Detection. Gastroenterology. 2022 07; 163(1):21-27.Gastroenterology2022-03-23T00:00:002022DETECT: Development of Technologies for Early HCC Detection.35066788Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Lederman RI, Frank E, Sohl JJ, Stadler ZK, Erick TK, Peppercorn J, Winer EP, Silverman SG, Come SE, Lin NUBreast cancer research and treatmentPerceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Res Treat. 2022 Feb; 192(1):201-210.Breast Cancer Res Treat2022-01-23T00:00:002022Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings.35149538Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea A, Swisher EM, Matulonis UA, Wulf GM, Mayer ELClinical cancer research : an official journal of the American Association for Cancer ResearchPhase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 04 14; 28(8):1493-1499.Clin Cancer Res2022-04-14T00:00:002022Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.Authorship 10440534Authorship 1044216235434236Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PAGynecologic oncology reportsA phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974.Gynecol Oncol Rep2022-03-31T00:00:002022A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.35443043Liu M, Tayob N, Penter L, Sellars M, Tarren A, Chea V, Carulli I, Huang T, Li S, Cheng SC, Le P, Frackiewicz L, Fasse J, Qi C, Liu JF, Stover EH, Curtis J, Livak KJ, Neuberg D, Zhang G, Matulonis UA, Wu CJ, Keskin DB, Konstantinopoulos PAClinical cancer research : an official journal of the American Association for Cancer ResearchImproved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clin Cancer Res. 2022 08 02; 28(15):3356-3366.Clin Cancer Res2022-08-02T00:00:002022Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer.Authorship 10457701835538105Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EPNPJ breast cancerA prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ Breast Cancer. 2022 May 10; 8(1):63.NPJ Breast Cancer2022-05-10T00:00:002022A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.Authorship 10482011135715538Sella T, Exman P, Ren S, Freret TS, Economy KE, Chen WY, Parsons HA, Lin NU, Moy B, Tung NM, Partridge AH, Tayob N, Mayer ELBreast cancer research and treatmentOutcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis. Breast Cancer Res Treat. 2022 Aug; 194(3):597-606.Breast Cancer Res Treat2022-06-17T00:00:002022Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis.Authorship 1048574335737367Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SMJAMA oncologyPrognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022 08 01; 8(8):1177-1183.JAMA Oncol2022-08-01T00:00:002022Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.Authorship 1049328635775874Sella T, Zheng Y, Tan-Wasielewski Z, Rosenberg SM, Poorvu PD, Tayob N, Ruddy KJ, Gelber SI, Tamimi RM, Schapira L, Come SE, Peppercorn JM, Borges VF, Partridge AH, Ligibel JACancerBody weight changes and associated predictors in a prospective cohort of young breast cancer survivors. Cancer. 2022 09 01; 128(17):3158-3169.Cancer2022-07-01T00:00:002022Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors.Authorship 10510552Authorship 1050747735841843Leone JP, Graham N, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Leone J, Vallejo CT, Winer EP, Lin NU, Tayob NEuropean journal of cancer (Oxford, England : 1990)Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. Eur J Cancer. 2022 09; 173:20-29.Eur J Cancer2022-07-13T00:00:002022Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.35867057Parikh ND, Tayob N, Al-Jarrah T, Kramer J, Melcher J, Smith D, Marquardt P, Liu PH, Tang R, Kanwal F, Singal AGJAMA network openBarriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort. JAMA Netw Open. 2022 07 01; 5(7):e2223504.JAMA Netw Open2022-07-01T00:00:002022Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort.Authorship 10515251835900726Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UAJAMA oncologyEvaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.JAMA Oncol2022-09-01T00:00:002022Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.Authorship 10622265Authorship 10582436Authorship 10613757Authorship 10619232Authorship 10586492Authorship 10614092Authorship 10551534Authorship 10586583Authorship 10626971336031091Choi J, Tayob N, Lim YSClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationDetecting Early Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Using Longitudinal a-Fetoprotein Screening. Clin Gastroenterol Hepatol. 2023 06; 21(6):1590-1597.Clin Gastroenterol Hepatol2022-08-27T00:00:002022Detecting Early Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Using Longitudinal a-Fetoprotein Screening.36450763Sella T, Zheng Y, Tayob N, Ruddy KJ, Freedman RA, Dang C, Yardley D, Isakoff SJ, Valero V, DeMeo M, Burstein HJ, Winer EP, Wolff AC, Krop I, Partridge AH, Tolaney SMNPJ breast cancerTreatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). NPJ Breast Cancer. 2022 Nov 30; 8(1):127.NPJ Breast Cancer2022-11-30T00:00:002022Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT).36089157Parikh ND, Tayob N, Singal AGJournal of hepatologyBlood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? J Hepatol. 2023 01; 78(1):207-216.J Hepatol2022-09-08T00:00:002022Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?36252998Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SMJournal for immunotherapy of cancerPhase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer. 2022 10; 10(10).J Immunother Cancer2022-10-01T00:00:002022Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.36163163Freedman RA, Li T, Sedrak MS, Hopkins JO, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong A, Tiwari A, McAllister SS, Mittendorf EA, Miller PG, Gibson CJ, Burstein HJJournal of geriatric oncology'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer. J Geriatr Oncol. 2023 Jan; 14(1):101377.J Geriatr Oncol2022-09-23T00:00:002022'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.36327124Tarantino P, Tayob N, Tolaney SMJAMA oncologyAssociation of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer-Reply. JAMA Oncol. 2023 01 01; 9(1):147-148.JAMA Oncol2023-01-01T00:00:002023Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer-Reply.36215125Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, McDonnell DP, Krop IE, Winer EP, Stewart C, Getz G, Jeselsohn RClinical cancer research : an official journal of the American Association for Cancer ResearchClinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2022 12 01; 28(23):5066-5078.Clin Cancer Res2022-12-01T00:00:002022Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.35937580Pudakalakatti S, Audia A, Mukhopadhyay A, Enriquez JS, Bourgeois D, Tayob N, Zacharias NM, Millward SW, Carson D, Farach-Carson MC, Lang FF, Heimberger AB, Bhat KP, Bhattacharya PKReports (MDPI)NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors. Reports (MDPI). 2021 Dec; 4(4).Reports (MDPI)2021-10-01T00:00:002021NMR Spectroscopy-Based Metabolomics of Platelets to Analyze Brain Tumors.36048535Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, L?nning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GMClinical cancer research : an official journal of the American Association for Cancer ResearchMutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clin Cancer Res. 2022 11 01; 28(21):4714-4723.Clin Cancer Res2022-11-01T00:00:002022Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.Authorship 1064957436858723Tolaney SM, Tarantino P, Graham N, Tayob N, Par? L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EPThe Lancet. OncologyAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 03; 24(3):273-285.Lancet Oncol2023-03-01T00:00:002023Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.Authorship 10660442436945501Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VAmedRxiv : the preprint server for health sciencesCirculating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. medRxiv. 2023 Mar 08.medRxiv2023-03-08T00:00:002023Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.Authorship 1068794537042724Mayerhofer C, Sedrak MS, Hopkins JO, Li T, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong AR, Tiwari A, McAllister SS, Mittendorf EA, Gibson CJ, Burstein HJ, Kim AS, Freedman RA, Miller PGJournal of the National Cancer InstituteClonal hematopoiesis in older patients with breast cancer receiving chemotherapy. J Natl Cancer Inst. 2023 08 08; 115(8):981-988.J Natl Cancer Inst2023-08-08T00:00:002023Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.Authorship 106984818Authorship 10698191137192427Trapani D, Jin Q, Block CC, Freedman RA, Lin NU, Tarantino P, Mittendorf EA, King TA, Lester SC, Brock JE, Tayob N, Bunnell CA, Tolaney SM, Burstein HJJCO oncology practiceIdentifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO Oncol Pract. 2023 08; 19(8):560-570.JCO Oncol Pract2023-05-16T00:00:002023Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement.37194964Weiss A, Li T, Desai NV, Tung NM, Poorvu PD, Partridge AH, Nakhlis F, Dominici L, Sinclair N, Spring LM, Faggen M, Constantine M, Krop IE, DeMeo M, Wrabel E, Alberti J, Chikarmane S, Tayob N, King TA, Tolaney SM, Winer EP, Mittendorf EA, Waks AGJournal of the American College of SurgeonsImpact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. J Am Coll Surg. 2023 08 01; 237(2):247-256.J Am Coll Surg2023-05-17T00:00:002023Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.Authorship 107200422Authorship 10737591137356327Leone JP, Graham N, Leone J, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Vallejo CT, Winer EP, Lin NU, Tayob NEuropean journal of cancer (Oxford, England : 1990)Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool. Eur J Cancer. 2023 08; 189:112930.Eur J Cancer2023-06-01T00:00:002023Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool.37450351Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, Garc?a-Pedrero J, Ca?adas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn RCancer researchEndocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 10 02; 83(19):3284-3304.Cancer Res2023-10-02T00:00:002023Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.Authorship 1074928237466644Kamounah S, Tayob N, Chiang S, Wei F, Park JK, Kwon HM, Feng Z, Chia D, Pedersen AML, Song YW, Wong DTWImmunoHorizonsImmunoassay Detects Salivary Anti-SSA/Ro-52 Autoantibodies in Seronegative Patients with Primary Sj?gren's Syndrome. Immunohorizons. 2023 07 01; 7(7):554-561.Immunohorizons2023-07-01T00:00:002023Immunoassay Detects Salivary Anti-SSA/Ro-52 Autoantibodies in Seronegative Patients with Primary Sj?gren's Syndrome.37597579Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VAAnnals of oncology : official journal of the European Society for Medical OncologyCirculating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906.Ann Oncol2023-08-18T00:00:002023Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.Authorship 108359724Authorship 10843772Authorship 1084524738019444Mayer EL, Tayob N, Ren S, Savoie JJ, Spigel DR, Burris HA, Ryan PD, Harris LN, Winer EP, Burstein HJBreast cancer research and treatmentA randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Feb; 204(1):123-132.Breast Cancer Res Treat2023-11-29T00:00:002023A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.38047578Weiss A, Jin Q, Waks AG, Yardley D, Spring LM, Wrabel E, Tayob N, Viale G, Krop IE, King TA, Metzger-Filho OJournal of the American College of SurgeonsAxillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. J Am Coll Surg. 2024 Mar 01; 238(3):303-311.J Am Coll Surg2023-12-04T00:00:002023Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial.Authorship 10861201038167908Guerriero JL, Lin JR, Pastorello RG, Du Z, Chen YA, Townsend MG, Shimada K, Hughes ME, Ren S, Tayob N, Zheng K, Mei S, Patterson A, Taneja KL, Metzger O, Tolaney SM, Lin NU, Dillon DA, Schnitt SJ, Sorger PK, Mittendorf EA, Santagata SNPJ breast cancerQualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer. 2024 Jan 02; 10(1):2.NPJ Breast Cancer2024-01-02T00:00:002024Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.Authorship 10866061938190580Morganti S, Gibson CJ, Jin Q, Santos K, Patel A, Wilson A, Merrill M, Vincuilla J, Stokes S, Lipsyc-Sharf M, Parker T, King TA, Mittendorf EA, Curigliano G, Hughes ME, Stover DG, Tolaney SM, Weeks LD, Tayob N, Lin NU, Garber JE, Miller PG, Parsons HAJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. J Clin Oncol. 2024 Jan 08; JCO2301071.J Clin Oncol2024-01-08T00:00:002024Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.Authorship 1089297738368741Tarantino P, Ajari O, Graham N, Vincuilla J, Parker T, Hughes ME, Tayob N, Garrido-Castro AC, Morganti S, King TA, Mittendorf EA, Curigliano G, Lin NU, Tolaney SMEuropean journal of cancer (Oxford, England : 1990)Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer. 2024 Apr; 201:113920.Eur J Cancer2024-02-10T00:00:002024Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.Authorship 1089680638421673Leone J, Hassett MJ, Freedman RA, Tolaney SM, Graham N, Tayob N, Vallejo CT, Winer EP, Lin NU, Leone JPJAMA oncologyMortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Feb 29.JAMA Oncol2024-02-29T00:00:002024Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.Authorship 10912981638503755G?mez Tejeda Za?udo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia JE, Pereslete A, Abravanel DL, Ferreira AR, Wrabel E, Helvie K, Hughes ME, Partridge AH, Overmoyer B, Lin NU, Tayob N, Tolaney SM, Wagle NNature communicationsExemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.Nat Commun2024-03-19T00:00:002024Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessor